



Under the Patent Law Revision Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/624,080
Sheet	1	of	2	Filing Date	July 21, 2003
				First Named Inventor	Ganjam V. Kalpana
				Art Unit	1645
				Examiner Name	to be assigned
				Attorney Docket Number	96700/819

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
MH	1	Biegel, J.A. et al., "Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors"; Cancer Res., Vol. 59, pp 74-9 (1999).		
	2	BUKOVSKY, A. et al., "Lack of integrase can markedly affect human immunodeficiency virus type 1 particle production in the presence of an active viral protease"; J. Virol., Vol. 70, No. 10, pp 6820-25 (1996).		
	3	CHENG, S.W. et al., "c MYC interacts with INI1/hSNF5 and requires the SWI/SNF complex for transactivation function"; Nat. Genet., Vol. 22, No. 1, pp 102-05 (1999).		
	4	ENGLEMAN, A. et al., "Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication"; J. Virol., Vol. 69, No. 5, pp 2729-36 (1995).		
	5	FLETCHER, T.M. et al. "Complementation of integrase function in HIV-1 virions"; EMBO. J., Vol. 16, No. 16, pp 5123-38 (1997).		
	6	KALPANA, G.V. et al., "Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5"; Science, Vol. 266, pp 2002-6 (1994).		
	7	KINGSTON, R.E. et al., "ATP-dependent remodeling and acetylation as regulators of chromatin fluidity"; Genes & Dev., Vol. 13, pp 2339-52 (1999).		
	8	LEAVITT, A.D., et al., "Human Immunodeficiency Virus Type 1 Integrase Mutants Retain In Vitro Integrase Activity yet Fail to Integrate Viral DNA Efficiently during Infection"; J. Virol., Vol. 70, No. 2, pp 721-28 (1996).		
	9	LEE, D. et al., "Interaction of E1 and hSNF5 proteins stimulates replication of human papillomavirus DNA"; Nature, Vol. 399, pp 487-91 (1999).		
▼	10	LEE, D. et al., "SWI/SNF complex interacts with tumor suppressor p53 and is necessary for the activation of p53 mediated transcription"; J. Biol. Chem., Vol. 277, No. 25, pp 22330-37 (2002).		

Examiner Signature	/Michelle Horning/	Date Considered	08/14/2006
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<i>Complete if Known</i>			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number		10/624,080	
		Filing Date		July 21, 2003	
		First Named Inventor		Ganjam V. Kalpana	
		Art Unit		1645	
		Examiner Name		to be assigned	
Sheet	2	of	2	Attorney Docket Number	96700/819

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published..			
MH	11	MOROZOV, A., et al., "Structure-function analysis of integrase interactor 1/hSNF5L1 reveals differential properties of two repeat motifs present in the highly conserved region"; Proc. Natl. Acad. Sci. USA, Vol. 95, pp 1120-25 (1998).			
	12	NAKAMURA, T. et al., "Lack of infectivity of HIV-1 integrase zinc finger-like domain mutant with morphologically normal maturation"; Biochem. Biophys. Res. Commun., Vol. 239, pp 715-22 (1997).			
	13	ROZENBLATT-ROSEN, O., et al., "The C terminal SET domains of ALL 1 and TRITHORAX interact with the INI1 and SNR1 proteins, components of the SWI/SNF complex"; Proc. Natl. Acad. Sci. USA, Vol. 95, pp 4152-57 (1998).			
	14	VERSTEEGE, I. et al., "Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer"; Nature, Vol. 394, pp 203-06 (1998).			
	15	WANG, W. et al., "Purification and biochemical heterogeneity of the mammalian SWI-SNF complex"; EMBO J., Vol. 15, pp 5370-82 (1996).			
	16	WISKERCHEN et al., "Human immunodeficiency virus type 1 integrase: Effects of mutations on viral ability to integrate, direct viral gene expression from unintegrated viral DNA templates, and sustain viral propagation in primary cells"; J. Virol., Vol. 69, No. 1, pp 376-86 (1995).			
	17	WU, D.Y. et al., "Epstein Barr virus nuclear protein 2 (EBNA2) binds to a component of the human SNF-SWI complex, hSNF5/INI1"; J. Virol., Vol. 70, No. 9, pp 6020-28 (1996).			
	18	WU, X. et al., "Human immunodeficiency Virus type 1 integrase protein promotes reverse transcription through specific interactions with the nucleoprotein reverse transcription complex"; J. Virol., Vol. 73, No. 3, pp 2126-35 (1999).			
	19	YUNG, E. et al., "Inhibition of HIV-1 virion production by a transdominant mutant of integrase interactor 1"; Nature Med., Vol. 7, No. 8, pp 920-26 (2001).			
↓	20	CHIN, A., "On the preparation and utilization of isolated and purified oligonucleotides." Katherine R. Everett Law Library of the University of North Carolina, March 14, 2002. (on attached CD-ROM)			

Examiner Signature	/Michelle Horning/	Date Considered	08/14/2006
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.